MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

For the quarter ending 2025-09-30, ADPT had $11,840K increase in cash & cash equivalents over the period. -$7,536K in free cash flow.

Cash Flow Overview

Change in Cash
$11,840K
Free Cash flow
-$7,536K

Unit: Thousand (K) dollars (except for numbers of shares and EPS)
Cash Flow
2025-09-30
2025-06-30
Net income (loss)
9,545 -55,423
Depreciation expense
3,977 8,391
Noncash lease expense
1,350 2,642
Share-based compensation expense
13,257 25,506
Intangible assets amortization
428 842
Investment amortization
516 1,708
Impairment of long-lived assets
0 -
Inventory reserve
-6 -46
Noncash interest expense
-1,728 287
Other
-434 -43
Accounts receivable, net
536 2,566
Inventory
1,347 -359
Prepaid expenses and other current assets
2,524 8
Accounts payable and accrued liabilities
5,896 -6,396
Operating lease right-of-use assets and liabilities
-2,567 -5,230
Deferred revenue
-32,790 -7,612
Other
0 -5
Net cash used in operating activities
-7,127 -40,914
Purchases of property and equipment
409 1,914
Purchases of marketable securities
33,191 101,792
Proceeds from maturities of marketable securities
50,883 132,625
Net cash provided by investing activities
17,283 28,919
Proceeds from exercise of stock options
1,684 7,061
Net cash provided by financing activities
1,684 7,061
Net increase (decrease) in cash, cash equivalents and restricted cash
11,840 -4,934
Cash and cash equivalents at beginning of period
50,817 -
Cash and cash equivalents at end of period
57,723 -
Unit: Thousand (K) dollars

Time Plot

Show the time plot by selecting a row from the table.

Adaptive Biotechnologies Corp (ADPT)

Adaptive Biotechnologies Corp (ADPT)